Collaboration Capitalizes On Alucio's Flagship Beacon Platform and Envision's Global Leadership in Medical Strategy and Healthcare Communications
SAN FRANCISCO and HORSHAM, UK., Oct. 6, 2022 /PRNewswire-PRWeb/ -- Envision Pharma Group (Envision) and Alucio today announced a global partnership to power impactful, scientific exchange and deliver additional value for life science customers.
By combining Alucio's innovative Beacon scientific exchange platform and technology with Envision's extensive medical affairs experience and scientific content development expertise, a broader set of life science companies will have the ability to assemble, refine, and adapt their scientific content with ease. Beacon is a modern content activation and healthcare professional engagement platform built specifically for medical science liaisons, medical affairs professionals, and market access teams.
Through this collaboration, Envision will provide strategic, insight-driven communications expertise with agile content development approaches to assist medical affairs and market access teams in taking full advantage of the Beacon platform and future Alucio technology products.
More broadly, this global partnership has the potential to transform current industry standards in stakeholder engagement by redefining best practice content development processes and leveraging technology to create powerful, personalized scientific exchanges. Through a user-centric approach, the companies will seek to enhance and integrate technology solutions that deliver real-time data and analytics to inform strategy and aid customer decision-making.
"Envision is a recognized, global leader within the medical affairs space. We are very excited about the potential of this partnership to bring the benefits of our modern scientific exchange platform to an even broader network and establish best practice in the context of content development, deployment, and engagement," said Dave Gulezian, Alucio Co-Founder and Chief Executive Officer. "We also look forward to collaborating to identify new opportunities to address emerging customer needs."
Envision's Chief Executive Officer, Meg Heim, added, "We have been impressed with what Alucio has built with Beacon and the momentum they have generated within the medical affairs space. We're equally excited to align our medical strategy, agile content development, and communications expertise with Alucio's technology capabilities to further enhance our customers' stakeholder engagement through a personalized, omni-channel approach."
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: http://www.envisionpharmagroup.com
About Alucio
Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry. Alucio's flagship product, Beacon, is a modern, cloud-based scientific exchange platform that enhances scientific dialogue and engagement between life science companies and healthcare professionals. For more information, please visit the company's website at http://www.alucio.io
Media Contact
Lisa Amin, Alucio, 925-788-3533, [email protected]
Marsha Caplin, Envision Pharma Group, +44 (0) 7557 083549, [email protected]
SOURCE Alucio
Share this article